EMA Withdrawn: Thelin (sitaxentan sodium) — Pfizer Ltd.

View source ↗

Summary

Thelin (sitaxentan sodium) has been withdrawn from the market by Pfizer Ltd., with a status of Withdrawn in the EMA record.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension
• Pulmonary Hypertension

Drugs mentioned

• Thelin (sitaxentan)

Snippet

Status: Withdrawn. Therapeutic area: Hypertension, Pulmonary. MAH: Pfizer Ltd.. Decision date: 06/01/2011